BioSpace News Archive

Jaguar Health, Inc. today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company’s Scientific Advisory Board (SAB).

Palisade Bio, Inc. today provided a clinical program update for its ead product candidate, LB1148, a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage.

Peptilogics, a clinical-stage biotechnology company, today announced top-line interim data of PLG0206 in PJI patients from their ongoing Phase 1b trial.

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer.

Dompé farmaceutici announced today new peer-reviewed data demonstrating that small changes in the SARS-CoV-2 Spike (S)-protein sequence can eliminate its effect in inducing coagulation.

Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present on Tuesday, June 6, 2023 at 4:15 PM ET in Room 103 at the BIO International Convention being held in Boston, MA.

The Insight Partners published latest research report on “Clinical Trial Imaging Market Share Report, Size, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Modality, Offering, and End User”, the global market size is expected to reach USD 2,480.32 million by 2028 from USD 1,610.70 million in 2022;

A new analysis led by NYU Grossman School of Medicine and the National Drug Early Warning System (NDEWS) at the University of Florida found a 349 percent rise in seizures of illicit ketamine by drug enforcement throughout the United States from 2017 through 2022.

Pixium Vision SA informs its shareholders that its Annual Meeting of the Company will be held on June 13, 2023, at 2.00 pm CET at the headquarter of Pixium Vision, 74 rue du faubourg Saint Antoine in Paris.

AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development.